IBRANCE(R) (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
NEW YORK--(Healthcare Sales & Marketing Network)--Pfizer Inc. (PFE) today announced that the European Commission (EC) has approved IBRANCE® (palbociclib) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor ... Biopharmaceuticals, Oncology, Regulatory Pfizer, IBRANCE, palbociclib, HR+/HER2, breast cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Marketing | Pfizer | Pharmaceuticals | Women